ROSSMAX Business Summary

Rossmax International Ltd. (4121.TWO) operates a vertically integrated business model focused on the research, development, and global distribution of diagnostic medical devices. The company generates the majority of its revenue through its Medical Device segment, which specializes in chronic disease management tools including digital blood pressure monitors, nebulizers, pulse oximeters, and infrared thermometers. Secondary revenue streams are derived from its Retail Channel and Investment departments, supported by a digital ecosystem centered on the Rossmax Healthstyle app for integrated health data management. Within the global market, Rossmax competes directly with Omron Healthcare, Microlife Corporation, A&D Company, and Yuwell. The company distinguishes itself by offering clinically validated, professional-grade diagnostic equipment at a competitive price point, positioning itself as a high-value alternative to premium Japanese and European brands in both consumer and clinical settings. Founded in 1988, Rossmax is led by Chairman and General Manager Chih-Ping (JP) Liu, who has steered the company since its early development and holds an academic background from National Chengchi University. The executive leadership team includes Deputy General Manager of Finance Cherry Chang and R&D Associate Managers Gary Hung and Chuan-ying Wang, who oversee the firm’s technical innovation and quality control standards. The company’s governance is supported by a seasoned board of directors, including notable members such as Li-Heng Huang and Te-Lan Wen. Significant institutional backing is provided by investors such as Purzer Pharmaceutical Co., Ltd. and Shenghe Investment Co., Ltd., reflecting the company's strategic integration within the broader Taiwanese healthcare and pharmaceutical ecosystem.